The US Food and Drug Administration announced yesterday that it has approved a coblistered triple combination of AZT, 3TC and nevirapine manufactured by the South African company Aspen Pharmacare.

The generic triple combination is composed of fixed dose tablets containing AZT (zidovudine) and 3TC (lamivudine), co-packaged with nevirapine tablets. It is the first generic fixed dose antiretroviral product to be approved by the FDA under new regulations introduced last May.

The product has received tentative approval, which means that it can be purchased by the President’s Emergency Plan for AIDS Relief (PEPFAR) for use in developing countries, but may not be marketed in the United States.

Aspen has not yet announced a price for the product, which contains drugs manufactured under voluntary licenses granted by GlaxoSmithKLine (Combivir) and Boehringer Ingelheim (Viramune).

aidsmap resources

latest news

• HIV/TB epidemic in Eastern Europe a 'public health disaster'
• Low bone mineral density common in HIV-positive men
• Circumcision may protect HIV-negative gay men from syphilis
• HIV 'exposure' from bite forms basis for terrorism charge in US case
• First hint of a hepatitis C vaccine?
• Pregnancy, not nevirapine cause of liver toxicities in HIV-positive women
• Surviving to die of something else: AIDS is a rare cause of death in old people with HIV
• New EACS guidelines address co-morbidities and diseases of age
• Multiple pregnancies a safe option for women with HIV
• Small case series looks at etravirine during pregnancy